Natixis Advisors LLC Sells 148,956 Shares of Healthpeak Properties, Inc. $DOC

Natixis Advisors LLC lowered its holdings in Healthpeak Properties, Inc. (NYSE:DOC) by 32.2% in the 4th quarter, HoldingsChannel reports. The firm owned 313,580 shares of the real estate investment trust’s stock after selling 148,956 shares during the quarter. Natixis Advisors LLC’s holdings in Healthpeak Properties were worth $5,042,000 as of its most recent SEC filing.

Several other large investors have also modified their holdings of the business. State Street Corp raised its holdings in shares of Healthpeak Properties by 1.8% in the 3rd quarter. State Street Corp now owns 49,498,109 shares of the real estate investment trust’s stock valued at $947,889,000 after purchasing an additional 895,460 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Healthpeak Properties by 41.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 28,236,534 shares of the real estate investment trust’s stock valued at $540,730,000 after purchasing an additional 8,212,504 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of Healthpeak Properties by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 19,534,041 shares of the real estate investment trust’s stock valued at $312,959,000 after purchasing an additional 123,274 shares in the last quarter. Dimensional Fund Advisors LP raised its holdings in shares of Healthpeak Properties by 4.1% in the 3rd quarter. Dimensional Fund Advisors LP now owns 10,228,560 shares of the real estate investment trust’s stock valued at $195,873,000 after purchasing an additional 400,900 shares in the last quarter. Finally, Bank of America Corp DE raised its holdings in shares of Healthpeak Properties by 28.5% in the 3rd quarter. Bank of America Corp DE now owns 9,936,934 shares of the real estate investment trust’s stock valued at $190,292,000 after purchasing an additional 2,206,222 shares in the last quarter. Institutional investors own 93.57% of the company’s stock.

Healthpeak Properties Trading Down 0.2%

NYSE DOC opened at $19.76 on Tuesday. The company has a quick ratio of 2.96, a current ratio of 2.96 and a debt-to-equity ratio of 1.15. The firm has a market cap of $13.62 billion, a PE ratio of 61.74, a price-to-earnings-growth ratio of 3.09 and a beta of 1.05. The company has a 50 day moving average price of $18.02 and a 200 day moving average price of $17.41. Healthpeak Properties, Inc. has a 52 week low of $15.70 and a 52 week high of $20.27.

Healthpeak Properties (NYSE:DOC) last posted its quarterly earnings data on Tuesday, May 5th. The real estate investment trust reported $0.45 EPS for the quarter, topping the consensus estimate of $0.43 by $0.02. The firm had revenue of $752.95 million during the quarter, compared to analyst estimates of $694.59 million. Healthpeak Properties had a net margin of 7.73% and a return on equity of 2.61%. Healthpeak Properties’s revenue was up 7.1% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.46 EPS. Healthpeak Properties has set its FY 2026 guidance at 1.710-1.750 EPS. As a group, sell-side analysts forecast that Healthpeak Properties, Inc. will post 1.74 EPS for the current fiscal year.

Healthpeak Properties Dividend Announcement

The company also recently disclosed a monthly dividend, which will be paid on Friday, June 26th. Investors of record on Monday, June 15th will be paid a dividend of $0.1017 per share. This represents a c) annualized dividend and a dividend yield of 6.2%. The ex-dividend date is Monday, June 15th. Healthpeak Properties’s payout ratio is 381.25%.

Analyst Ratings Changes

DOC has been the subject of several recent research reports. Weiss Ratings upgraded shares of Healthpeak Properties from a “hold (c-)” rating to a “hold (c)” rating in a report on Friday, May 8th. Wells Fargo & Company boosted their price target on shares of Healthpeak Properties from $18.00 to $20.00 and gave the company an “equal weight” rating in a report on Monday, June 1st. Robert W. Baird boosted their price target on shares of Healthpeak Properties from $19.00 to $21.00 and gave the company an “outperform” rating in a report on Wednesday, May 13th. Morgan Stanley boosted their price target on shares of Healthpeak Properties from $18.00 to $20.00 and gave the company an “overweight” rating in a report on Friday, May 22nd. Finally, Scotiabank boosted their price target on shares of Healthpeak Properties from $19.00 to $21.00 and gave the company a “sector perform” rating in a report on Wednesday, May 27th. Four investment analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $19.38.

Insider Activity at Healthpeak Properties

In related news, insider Scott R. Bohn sold 10,989 shares of the business’s stock in a transaction that occurred on Tuesday, May 12th. The shares were sold at an average price of $19.45, for a total transaction of $213,736.05. Following the completion of the transaction, the insider owned 7,636 shares in the company, valued at $148,520.20. The trade was a 59.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.23% of the stock is currently owned by company insiders.

Healthpeak Properties Company Profile

Healthpeak Properties, Inc is a real estate investment trust (REIT) specializing in healthcare-related real estate. Headquartered in Irvine, California, the company owns, develops and acquires a diversified portfolio of properties that cater to the evolving needs of the healthcare industry. Its investments span life science research facilities, medical office buildings and senior housing communities, positioning Healthpeak as a key provider of specialized real estate assets.

Within its life science segment, Healthpeak develops and leases laboratory and research space to biotechnology, pharmaceutical and other life science companies.